VPVictoria Palafox-Sanchez

Victoria Palafox-Sanchez

*This is an algorithmically generated author record based on publicly available information.

Victoria Palafox-Sanchez has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cannabidiol attenuates kidney injury and mitochondrial calcium dysregulation in experimental cardiorenal syndrome.

    by Hector Chapoy Villanueva, Gerardo García-Rivas, Luis Luevano Martinez, Victoria Palafox-Sanchez, Emanuel Guajardo-Correa, Carolina Morales-Ochoa, Hipolito Miranda, Noemi Garcia, Karla Barragan-Jimenez, Dulce Gomez Trujillo, et al.

    Cardiorenal syndrome (CRS) is characterized by bidirectional heart–kidney dysfunction in which oxidative stress, inflammation, and mitochondrial dysfunction drive progressive kidney injury, but the role of mitochondrial calcium (Ca²⁺) handling through the mitochondrial calcium uniporter (MCU) complex remains unclear. Here we show, in a mouse model of CRS induced by angiotensin II and L-NAME in male mice (C57BL/6), that renal mitochondria exhibit increased MCU expression, reduced Ca²⁺ retention capacity, and greater susceptibility to Ca²⁺-induced permeability transition, alongside impaired respiration, reduced PGC-1α and TFAM expression, oxidative stress, and inflammatory activation. Cannabidiol (CBD) attenuates renal dysfunction and structural injury, restores mitochondrial respiratory capacity and complex I activity, normalizes MCU expression, and partially improves mitochondrial Ca²⁺ handling, independently of blood pressure reduction. These findings identify MCU-dependent mitochondrial Ca²⁺ dysregulation as a candidate mechanism linking mitochondrial dysfunction to renal injury in CRS, and a potential target for CBD’s nephroprotective effects.